Live Coverage Of The Panobinostat FDA Advisory Committee Meeting

The Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration will convene this morning to review panobinostat, and The Myeloma Beacon will provide live coverage of the meeting.
Beacon staff members will post frequent updates at the webpage for this article as the meeting proceeds. Coverage will begin at the start of the meeting at 8 a.m. Eastern Time, which is when the review of panobinostat (Farydak) is scheduled to begin.
The Swiss pharmaceutical company Novartis (NYSE:NVS) submitted an application to the Food and Drug Administration (FDA) this March to have panobinostat approved for the treatment of relapsed multiple myeloma (see related Beacon news).
The FDA is expected to make a decision about panobinostat’s application by the end of this month. It also has the option, however, of extending this deadline if it feels it needs additional time to complete its review.
During today’s meeting, the Oncologic Drugs Advisory Committee (ODAC), which advises the FDA regarding cancer drugs, will review briefing information that the FDA released for the committee members on Tuesday (see related Beacon news).
Representatives from Novartis, including scientific advisers to the company, also will be given an opportunity to present information during the meeting, as will members of the public.
At the end of the meeting, members of the ODAC will discuss the material they have been presented and vote whether they believe the risk/benefit profile of panobinostat is favorable.
The ODAC vote will generally be interpreted as a recommendation for, or against, the FDA approving panobinostat. The FDA is not legally required to follow the recommendations of its advisory committees; however, it usually does.
Please check back at 8 a.m. Eastern Time today when the Beacon’s live coverage of the advisory committee meeting will begin right here.
Our updates from the meeting will appear directly below and you will receive notifications here when new updates are ready. Just click on the notification when it appears to display the new notifications.
Notifications may not appear on older version of Internet Explorer (version 8 or older). Also, to reduce the load on the Beacon's webserver, commenting on this article will be turned off during the meeting.
Related Articles:
- None Found
I am taking this drug panobinostat along with Revlimid and dex. If this drug is not approved, does that mean my clinical trial will stop? Thank you.
Thanks to the Beacon staff for letting us mm patients in on the ODAC meeting for panobinostat. Hope that the benefits/risk issue can be resolved. And thanks, in advance, for keeping us posted on further developments.
Get new Myeloma Beacon articles by email.